Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2022

View Archived Issues

Novel microRNA panel predicts immunotherapy efficacy in NSCLC

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical patents ADCs targeting B7-H3

Shanghai Jemincare Pharmaceuticals, Jiangxi Jemincare Group present SLC9A3 inhibitors

New pantetheinase inhibitors discovered at Shanghai Meiyue Biotech Development

Shanghai Institute of Materia Medica describes thyroid hormone receptor agonists

New ROCK-1/2 inhibitors identified at Chiesi Farmaceutici

Novel vaccination strategy using AMP-CpG against EBV infection shows promise in vivo

Explant glioblastoma model may allow early precision treatment of patients

Aramchol shows effects in preclinical models of lung and gastrointestinal fibrosis

DS-17701585, EP300/CBP inhibitor with efficacy in lung squamous cell carcinoma xenograft

GLP-1R agonist PF-1801 seen useful to treat polymyositis

Oral and topical CF-602 significantly reduces erectile dysfunction in vivo

Researchers develop a hepatitis E model in rats

Limitations of certain mouse models for sickle cell research highlighted

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...